EMA gives green light for 8 new medicines

The European Medicine Agency’s key decision-making committee on human medicines (CHMP), has recommended eight medicines for approval at its June meeting.  The Committee recommended granting a conditional marketing authorisation for Abecma (idecabtagene vicleucel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three previous therapies, and whose cancer has worsened since receiving the last treatment. […]